SPR Therapeutics, a private medical device company focused on providing patients with pain relief without opioids or surgery, announced today it has raised $37 million in an oversubscribed Series D growth equity financing. The investment will be used to accelerate the rapidly growing commercial uptake of its FDA-cleared SPRINTĀ® Peripheral Nerve Stimulation (PNS) System, to fund additional clinical research, and to advance next generation technology.